RecruitingNCT06279572

Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy

Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy: Opportunities for T-Cell Directed Immunotherapy

Sponsor

Mayo Clinic

Enrollment

80 participants

Start Date

Apr 22, 2021

Study Type

OBSERVATIONAL

Conditions

Acute Myeloid Leukemia

Summary

This study investigates the immune profile of patients receiving treatment with venetoclax plus azacitidine for acute myeloid leukemia (AML). Studying the information gathered from the immune profile from blood and bone marrow samples may help researchers understand the associated responses to the treatment of patients undergoing therapy of venetoclax plus azacitidine and create future immune based treatment approaches.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at how the immune system responds in patients with acute myeloid leukemia (AML) — a fast-growing cancer of the blood — who are receiving a combination of two chemotherapy drugs: azacitidine and venetoclax. Researchers want to understand which immune cells are active during this treatment. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with acute myeloid leukemia (AML) - You are receiving azacitidine and venetoclax as your first (treatment-naive) course of chemotherapy **You may NOT be eligible if...** - You are receiving azacitidine and venetoclax as a second or later round of treatment (salvage therapy) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.